⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
RDY News
Dr. Reddy's Laboratories Limited American Depositary Shares
Dr. Reddy’s Announces USFDA Acceptance to Review Its Biologics License Application (BLA) for Proposed Interchangeable Biosimilar, Abatacept
businesswire.com
RDY
Lancement du livre « Made in India - The story of Desh Bandhu Gupta, Lupin and Indian Pharma » (Fabriqué en Inde - L'histoire de Desh Bandhu Gupta, de Lupin et de la pharmacie indienne) à Mumbai USA - Français India - English
prnewswire.com
SUN
RDY
Dr. Reddy’s Announces the First-to-Market Launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC), the Generic Equivalent of Extra-Strength Pataday ® Once Daily Relief, in the U.S.
businesswire.com
RDY
RentRedi Recognized for Premier Customer Service by National Association of Realtors®
globenewswire.com
RDY
Trends and Market Growth Opportunities in the Alcohol Use Disorder Industry, 2025-2032
globenewswire.com
ALKS
TEVA
VTRS
RDY
SUN
Tour Operator Software Market Set to Surpass Valuation of US$ 2,236.7 Million By 2035 | Astute Analytica
globenewswire.com
RDY
Immutep and Dr. Reddy’s enters into Strategic Collaboration for Commercialisation of an Innovative Oncology Drug, Eftilagimod Alfa
globenewswire.com
IMMP
RDY
RentRedi Launches Spanish-Language Version of Tenant App, Plus Spanish Support, to Strengthen Landlord-Tenant Communication
globenewswire.com
RDY
Aurigene Oncology Limited gibt vielversprechende erste Daten aus den ersten beiden Kohorten der Phase-1-Studie zu AUR112 bekannt, einem oral verabreichten niedermolekularen Inhibitor von MALT1, bei wieder auftretenden oder hartnäckigen...
businesswire.com
RDY
Aurigene Oncology Limited annonce des données initiales encourageantes provenant des deux premiers groupes de l'étude de phase 1 évaluant l'AUR112, un inhibiteur oral à petites molécules de MALT1, pour les lymphopathies malignes...
businesswire.com
RDY